[
    {
        "molecule_name": "196",
        "protein_target_name": "NR2B",
        "binding_metric": "IC50",
        "value": "82",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nTABLE 1\nIn vitro NR2B affinity of the compounds of the presentinvention as obtained in the FLIPR assay\nExample number\tIC50 [nM]\n196\t82\n213\t23\n369\t04\n1200\t51\n1068\t77\n1002\t88\n5921\t01\n1822\t30\n5953\t15\n2433\t80\n7346\t43\n5197\t36\n542\t\n\n\nTABLE 2\nIn vitro NR2B affinity of the closest prior art compounds(examples 100, 105, 106 and 107 in WO2015/130905) as obtainedin the same FLIPR assay as compounds in table 1\nExample number in\tWO2015/130905\tIC50 [nM]\n100\t>8887\n105\t>9261\n106\t>9255\n107\t>9257\n\n\nCompound Plate Preparation\nThe compounds were prepared in DMSO at 300× the final assay concentrations of 1 and 5 μM.\n\n\nAs positive control Lidocaine at concentrations of 30 and 1000 μM was used."
    },
    {
        "molecule_name": "213",
        "protein_target_name": "NR2B",
        "binding_metric": "IC50",
        "value": "23",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nTABLE 1\nIn vitro NR2B affinity of the compounds of the presentinvention as obtained in the FLIPR assay\nExample number\tIC50 [nM]\n196\t82\n213\t23\n369\t04\n1200\t51\n1068\t77\n1002\t88\n5921\t01\n1822\t30\n5953\t15\n2433\t80\n7346\t43\n5197\t36\n542\t\n\n\nTABLE 2\nIn vitro NR2B affinity of the closest prior art compounds(examples 100, 105, 106 and 107 in WO2015/130905) as obtainedin the same FLIPR assay as compounds in table 1\nExample number in\tWO2015/130905\tIC50 [nM]\n100\t>8887\n105\t>9261\n106\t>9255\n107\t>9257\n\n\nCompound Plate Preparation\nThe compounds were prepared in DMSO at 300× the final assay concentrations of 1 and 5 μM.\n\n\nAs positive control Lidocaine at concentrations of 30 and 1000 μM was used."
    },
    {
        "molecule_name": "369",
        "protein_target_name": "NR2B",
        "binding_metric": "IC50",
        "value": "04",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nTABLE 1\nIn vitro NR2B affinity of the compounds of the presentinvention as obtained in the FLIPR assay\nExample number\tIC50 [nM]\n196\t82\n213\t23\n369\t04\n1200\t51\n1068\t77\n1002\t88\n5921\t01\n1822\t30\n5953\t15\n2433\t80\n7346\t43\n5197\t36\n542\t\n\n\nTABLE 2\nIn vitro NR2B affinity of the closest prior art compounds(examples 100, 105, 106 and 107 in WO2015/130905) as obtainedin the same FLIPR assay as compounds in table 1\nExample number in\tWO2015/130905\tIC50 [nM]\n100\t>8887\n105\t>9261\n106\t>9255\n107\t>9257\n\n\nCompound Plate Preparation\nThe compounds were prepared in DMSO at 300× the final assay concentrations of 1 and 5 μM.\n\n\nAs positive control Lidocaine at concentrations of 30 and 1000 μM was used."
    },
    {
        "molecule_name": "1200",
        "protein_target_name": "NR2B",
        "binding_metric": "IC50",
        "value": "51",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nTABLE 1\nIn vitro NR2B affinity of the compounds of the presentinvention as obtained in the FLIPR assay\nExample number\tIC50 [nM]\n196\t82\n213\t23\n369\t04\n1200\t51\n1068\t77\n1002\t88\n5921\t01\n1822\t30\n5953\t15\n2433\t80\n7346\t43\n5197\t36\n542\t\n\n\nTABLE 2\nIn vitro NR2B affinity of the closest prior art compounds(examples 100, 105, 106 and 107 in WO2015/130905) as obtainedin the same FLIPR assay as compounds in table 1\nExample number in\tWO2015/130905\tIC50 [nM]\n100\t>8887\n105\t>9261\n106\t>9255\n107\t>9257\n\n\nCompound Plate Preparation\nThe compounds were prepared in DMSO at 300× the final assay concentrations of 1 and 5 μM.\n\n\nAs positive control Lidocaine at concentrations of 30 and 1000 μM was used."
    },
    {
        "molecule_name": "1068",
        "protein_target_name": "NR2B",
        "binding_metric": "IC50",
        "value": "77",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nTABLE 1\nIn vitro NR2B affinity of the compounds of the presentinvention as obtained in the FLIPR assay\nExample number\tIC50 [nM]\n196\t82\n213\t23\n369\t04\n1200\t51\n1068\t77\n1002\t88\n5921\t01\n1822\t30\n5953\t15\n2433\t80\n7346\t43\n5197\t36\n542\t\n\n\nTABLE 2\nIn vitro NR2B affinity of the closest prior art compounds(examples 100, 105, 106 and 107 in WO2015/130905) as obtainedin the same FLIPR assay as compounds in table 1\nExample number in\tWO2015/130905\tIC50 [nM]\n100\t>8887\n105\t>9261\n106\t>9255\n107\t>9257\n\n\nCompound Plate Preparation\nThe compounds were prepared in DMSO at 300× the final assay concentrations of 1 and 5 μM.\n\n\nAs positive control Lidocaine at concentrations of 30 and 1000 μM was used."
    },
    {
        "molecule_name": "1002",
        "protein_target_name": "NR2B",
        "binding_metric": "IC50",
        "value": "88",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nTABLE 1\nIn vitro NR2B affinity of the compounds of the presentinvention as obtained in the FLIPR assay\nExample number\tIC50 [nM]\n196\t82\n213\t23\n369\t04\n1200\t51\n1068\t77\n1002\t88\n5921\t01\n1822\t30\n5953\t15\n2433\t80\n7346\t43\n5197\t36\n542\t\n\n\nTABLE 2\nIn vitro NR2B affinity of the closest prior art compounds(examples 100, 105, 106 and 107 in WO2015/130905) as obtainedin the same FLIPR assay as compounds in table 1\nExample number in\tWO2015/130905\tIC50 [nM]\n100\t>8887\n105\t>9261\n106\t>9255\n107\t>9257\n\n\nCompound Plate Preparation\nThe compounds were prepared in DMSO at 300× the final assay concentrations of 1 and 5 μM.\n\n\nAs positive control Lidocaine at concentrations of 30 and 1000 μM was used."
    },
    {
        "molecule_name": "5921",
        "protein_target_name": "NR2B",
        "binding_metric": "IC50",
        "value": "01",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nTABLE 1\nIn vitro NR2B affinity of the compounds of the presentinvention as obtained in the FLIPR assay\nExample number\tIC50 [nM]\n196\t82\n213\t23\n369\t04\n1200\t51\n1068\t77\n1002\t88\n5921\t01\n1822\t30\n5953\t15\n2433\t80\n7346\t43\n5197\t36\n542\t\n\n\nTABLE 2\nIn vitro NR2B affinity of the closest prior art compounds(examples 100, 105, 106 and 107 in WO2015/130905) as obtainedin the same FLIPR assay as compounds in table 1\nExample number in\tWO2015/130905\tIC50 [nM]\n100\t>8887\n105\t>9261\n106\t>9255\n107\t>9257\n\n\nCompound Plate Preparation\nThe compounds were prepared in DMSO at 300× the final assay concentrations of 1 and 5 μM.\n\n\nAs positive control Lidocaine at concentrations of 30 and 1000 μM was used."
    },
    {
        "molecule_name": "1822",
        "protein_target_name": "NR2B",
        "binding_metric": "IC50",
        "value": "30",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nTABLE 1\nIn vitro NR2B affinity of the compounds of the presentinvention as obtained in the FLIPR assay\nExample number\tIC50 [nM]\n196\t82\n213\t23\n369\t04\n1200\t51\n1068\t77\n1002\t88\n5921\t01\n1822\t30\n5953\t15\n2433\t80\n7346\t43\n5197\t36\n542\t\n\n\nTABLE 2\nIn vitro NR2B affinity of the closest prior art compounds(examples 100, 105, 106 and 107 in WO2015/130905) as obtainedin the same FLIPR assay as compounds in table 1\nExample number in\tWO2015/130905\tIC50 [nM]\n100\t>8887\n105\t>9261\n106\t>9255\n107\t>9257\n\n\nCompound Plate Preparation\nThe compounds were prepared in DMSO at 300× the final assay concentrations of 1 and 5 μM.\n\n\nAs positive control Lidocaine at concentrations of 30 and 1000 μM was used."
    },
    {
        "molecule_name": "5953",
        "protein_target_name": "NR2B",
        "binding_metric": "IC50",
        "value": "15",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nTABLE 1\nIn vitro NR2B affinity of the compounds of the presentinvention as obtained in the FLIPR assay\nExample number\tIC50 [nM]\n196\t82\n213\t23\n369\t04\n1200\t51\n1068\t77\n1002\t88\n5921\t01\n1822\t30\n5953\t15\n2433\t80\n7346\t43\n5197\t36\n542\t\n\n\nTABLE 2\nIn vitro NR2B affinity of the closest prior art compounds(examples 100, 105, 106 and 107 in WO2015/130905) as obtainedin the same FLIPR assay as compounds in table 1\nExample number in\tWO2015/130905\tIC50 [nM]\n100\t>8887\n105\t>9261\n106\t>9255\n107\t>9257\n\n\nCompound Plate Preparation\nThe compounds were prepared in DMSO at 300× the final assay concentrations of 1 and 5 μM.\n\n\nAs positive control Lidocaine at concentrations of 30 and 1000 μM was used."
    },
    {
        "molecule_name": "2433",
        "protein_target_name": "NR2B",
        "binding_metric": "IC50",
        "value": "80",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nTABLE 1\nIn vitro NR2B affinity of the compounds of the presentinvention as obtained in the FLIPR assay\nExample number\tIC50 [nM]\n196\t82\n213\t23\n369\t04\n1200\t51\n1068\t77\n1002\t88\n5921\t01\n1822\t30\n5953\t15\n2433\t80\n7346\t43\n5197\t36\n542\t\n\n\nTABLE 2\nIn vitro NR2B affinity of the closest prior art compounds(examples 100, 105, 106 and 107 in WO2015/130905) as obtainedin the same FLIPR assay as compounds in table 1\nExample number in\tWO2015/130905\tIC50 [nM]\n100\t>8887\n105\t>9261\n106\t>9255\n107\t>9257\n\n\nCompound Plate Preparation\nThe compounds were prepared in DMSO at 300× the final assay concentrations of 1 and 5 μM.\n\n\nAs positive control Lidocaine at concentrations of 30 and 1000 μM was used."
    },
    {
        "molecule_name": "7346",
        "protein_target_name": "NR2B",
        "binding_metric": "IC50",
        "value": "43",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nTABLE 1\nIn vitro NR2B affinity of the compounds of the presentinvention as obtained in the FLIPR assay\nExample number\tIC50 [nM]\n196\t82\n213\t23\n369\t04\n1200\t51\n1068\t77\n1002\t88\n5921\t01\n1822\t30\n5953\t15\n2433\t80\n7346\t43\n5197\t36\n542\t\n\n\nTABLE 2\nIn vitro NR2B affinity of the closest prior art compounds(examples 100, 105, 106 and 107 in WO2015/130905) as obtainedin the same FLIPR assay as compounds in table 1\nExample number in\tWO2015/130905\tIC50 [nM]\n100\t>8887\n105\t>9261\n106\t>9255\n107\t>9257\n\n\nCompound Plate Preparation\nThe compounds were prepared in DMSO at 300× the final assay concentrations of 1 and 5 μM.\n\n\nAs positive control Lidocaine at concentrations of 30 and 1000 μM was used."
    },
    {
        "molecule_name": "5197",
        "protein_target_name": "NR2B",
        "binding_metric": "IC50",
        "value": "36",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nTABLE 1\nIn vitro NR2B affinity of the compounds of the presentinvention as obtained in the FLIPR assay\nExample number\tIC50 [nM]\n196\t82\n213\t23\n369\t04\n1200\t51\n1068\t77\n1002\t88\n5921\t01\n1822\t30\n5953\t15\n2433\t80\n7346\t43\n5197\t36\n542\t\n\n\nTABLE 2\nIn vitro NR2B affinity of the closest prior art compounds(examples 100, 105, 106 and 107 in WO2015/130905) as obtainedin the same FLIPR assay as compounds in table 1\nExample number in\tWO2015/130905\tIC50 [nM]\n100\t>8887\n105\t>9261\n106\t>9255\n107\t>9257\n\n\nCompound Plate Preparation\nThe compounds were prepared in DMSO at 300× the final assay concentrations of 1 and 5 μM.\n\n\nAs positive control Lidocaine at concentrations of 30 and 1000 μM was used."
    },
    {
        "molecule_name": "100",
        "protein_target_name": "NR2B",
        "binding_metric": "IC50",
        "value": ">8887",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nTABLE 1\nIn vitro NR2B affinity of the compounds of the presentinvention as obtained in the FLIPR assay\nExample number\tIC50 [nM]\n196\t82\n213\t23\n369\t04\n1200\t51\n1068\t77\n1002\t88\n5921\t01\n1822\t30\n5953\t15\n2433\t80\n7346\t43\n5197\t36\n542\t\n\n\nTABLE 2\nIn vitro NR2B affinity of the closest prior art compounds(examples 100, 105, 106 and 107 in WO2015/130905) as obtainedin the same FLIPR assay as compounds in table 1\nExample number in\tWO2015/130905\tIC50 [nM]\n100\t>8887\n105\t>9261\n106\t>9255\n107\t>9257\n\n\nCompound Plate Preparation\nThe compounds were prepared in DMSO at 300× the final assay concentrations of 1 and 5 μM.\n\n\nAs positive control Lidocaine at concentrations of 30 and 1000 μM was used."
    },
    {
        "molecule_name": "105",
        "protein_target_name": "NR2B",
        "binding_metric": "IC50",
        "value": ">9261",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nTABLE 1\nIn vitro NR2B affinity of the compounds of the presentinvention as obtained in the FLIPR assay\nExample number\tIC50 [nM]\n196\t82\n213\t23\n369\t04\n1200\t51\n1068\t77\n1002\t88\n5921\t01\n1822\t30\n5953\t15\n2433\t80\n7346\t43\n5197\t36\n542\t\n\n\nTABLE 2\nIn vitro NR2B affinity of the closest prior art compounds(examples 100, 105, 106 and 107 in WO2015/130905) as obtainedin the same FLIPR assay as compounds in table 1\nExample number in\tWO2015/130905\tIC50 [nM]\n100\t>8887\n105\t>9261\n106\t>9255\n107\t>9257\n\n\nCompound Plate Preparation\nThe compounds were prepared in DMSO at 300× the final assay concentrations of 1 and 5 μM.\n\n\nAs positive control Lidocaine at concentrations of 30 and 1000 μM was used."
    },
    {
        "molecule_name": "106",
        "protein_target_name": "NR2B",
        "binding_metric": "IC50",
        "value": ">9255",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nTABLE 1\nIn vitro NR2B affinity of the compounds of the presentinvention as obtained in the FLIPR assay\nExample number\tIC50 [nM]\n196\t82\n213\t23\n369\t04\n1200\t51\n1068\t77\n1002\t88\n5921\t01\n1822\t30\n5953\t15\n2433\t80\n7346\t43\n5197\t36\n542\t\n\n\nTABLE 2\nIn vitro NR2B affinity of the closest prior art compounds(examples 100, 105, 106 and 107 in WO2015/130905) as obtainedin the same FLIPR assay as compounds in table 1\nExample number in\tWO2015/130905\tIC50 [nM]\n100\t>8887\n105\t>9261\n106\t>9255\n107\t>9257\n\n\nCompound Plate Preparation\nThe compounds were prepared in DMSO at 300× the final assay concentrations of 1 and 5 μM.\n\n\nAs positive control Lidocaine at concentrations of 30 and 1000 μM was used."
    },
    {
        "molecule_name": "107",
        "protein_target_name": "NR2B",
        "binding_metric": "IC50",
        "value": ">9257",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nTABLE 1\nIn vitro NR2B affinity of the compounds of the presentinvention as obtained in the FLIPR assay\nExample number\tIC50 [nM]\n196\t82\n213\t23\n369\t04\n1200\t51\n1068\t77\n1002\t88\n5921\t01\n1822\t30\n5953\t15\n2433\t80\n7346\t43\n5197\t36\n542\t\n\n\nTABLE 2\nIn vitro NR2B affinity of the closest prior art compounds(examples 100, 105, 106 and 107 in WO2015/130905) as obtainedin the same FLIPR assay as compounds in table 1\nExample number in\tWO2015/130905\tIC50 [nM]\n100\t>8887\n105\t>9261\n106\t>9255\n107\t>9257\n\n\nCompound Plate Preparation\nThe compounds were prepared in DMSO at 300× the final assay concentrations of 1 and 5 μM.\n\n\nAs positive control Lidocaine at concentrations of 30 and 1000 μM was used."
    }
]